If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Reyvow ® (lasmiditan) tablets CV
50 mg, 100 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Is there a pregnancy registry for Reyvow® (lasmiditan)?
A Reyvow (lasmiditan) pregnancy registry is available for healthcare providers and patients.
Reyvow (lasmiditan) Pregnancy Registry Enrollment Information
Pregnancy Registry Will Monitor Pregnancy Outcomes With Lasmiditan Exposure
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lasmiditan during pregnancy.1
Eligible women may self-enroll, or be enrolled by their healthcare provider into the Eli Lilly and Company Migraine Pregnancy Registry by
- accessing the registry website at www.migrainepregnancyregistry.com, or
- calling 1-833-464-4724.1
This registry is only available in the United States.
Enclosed Prescribing Information
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
1Reyvow [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.
Date of Last Review: August 04, 2022